The specification describes a nitrosourea derivative having the general formula: Cl--(CH.sub.2).sub.2 --N(NO)CO--NHR, wherein --NHR represents a 2-(1,3,4-thiadiazolyl)amino group, an amino residue of a neutral .alpha.-amino acid, or an amino residue of a neutral .alpha.-amino acid whose carboxyl group is amidated with 2-(1,3,4-thiadiazolyl)amine, or a pharmaceutically acceptable acid addition salt thereof. The above nitrosourea derivative and its salt are useful as antitumor drugs. The above nitrosourea derivative may be prepared either by nitrosating a urea derivative of the general formula: Cl--(CH.sub.2).sub.2 NHCONHR or by reacting N-(2-chloroethyl)-N-nitrosocarbamic acid or a reactive derivative thereof with an amino compound of the general formula: R--NH.sub.2.
该规范描述了一种硝基
脲衍
生物,其通式为:Cl--(CH.sub.2).sub.2 --N(NO)CO--NHR,其中--NHR代表2-(1,3,4-
噻二唑基)
氨基团,一种中性
α-氨基酸的
氨基残基,或者一种中性
α-氨基酸的
氨基残基,其羧基被2-(1,3,4-
噻二唑基)胺酰化,或其药用可接受的酸盐。上述硝基
脲衍
生物及其盐可用作
抗肿瘤药物。上述硝基
脲衍
生物可通过硝化通式为Cl--(CH.sub.2).sub.2 NHCONHR的
脲衍
生物,或者通过将N-(2-
氯乙基)-N-亚硝基甲酰胺或其反应衍
生物与通式为R--NH.sub.2的
氨基化合物反应来制备。